Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 0,23 € (+163,46%). La mediana è 0,23 € (+163,46%).
| Acquista |
5 |
| Mantieni |
5 |
| Vendi |
1 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Applied Therapeutics delisted from Nasdaq after takeover by Cycle Group
Applied Therapeutics has completed its merger with Cycle Group Holdings and is now an indirect wholly owned subsidiary of Cycle Group. Cycle Group subsidiary AT2B acquired all outstanding shares for $0.088 per share; shareholders also received a non-tradable CVR with potential payments of up to $0.40. Applied filed to suspend trading, delist and deregister with the SEC; the board and several executives resigned, and James Harrison took over leadership. Cycle is integrating the lead drug candidate Govorestat into its portfolio; analysts sharply cut ratings and price targets for Applied stock following the transaction. » Altro su de.investing.com
Cycle extends takeover offer for Applied Therapeutics
Cycle Group Holdings has extended the deadline for its takeover offer for Applied Therapeutics to 11:59 p.m. ET on January 29, 2026. Cycle is offering $0.088 per share in cash plus a non-tradable contingent value right; the price is close to the stock’s 52-week low. The board of directors of Applied Therapeutics unanimously recommends tendering the shares and warns that, if tendering is insufficient, liquidation and the immediate repayment of an $8.5 million promissory note to Cycle would likely follow. Financial data show a weak financial picture with negative EBITDA and significant financial challenges for Applied Therapeutics. » Altro su de.investing.com
Applied Therapeutics explores strategic alternatives and cuts 46% of workforce
Applied Therapeutics has launched a process to evaluate strategic options such as M&A, partnerships and licensing agreements to maximize shareholder value. At the same time, the company is reducing costs by cutting 46% of its workforce; it did not disclose exact employee numbers. The stock fell sharply last year and the company reported a negative EBITDA of USD 99.61 million, but says it has more cash than debt. Applied Therapeutics is reviewing FDA Type C meeting minutes for its lead candidate govorestat and considering next steps, after also agreeing a $75 million share sale facility with Cantor Fitzgerald. » Altro su de.investing.com
Applied Therapeutics stock plunges after uncertainty in FDA approval process for Govorestat
Applied Therapeutics shares fell about 55% in pre-market trading after the company said the next steps for a Govorestat approval filing, including a potential accelerated submission, have not been determined. Applied is waiting for the official FDA meeting minutes to decide how to proceed; it had previously aimed for a submission in Q3 2025. Govorestat is being developed to treat the rare neuropathy CMT‑SORD and already has multiple regulatory special designations in the US and Europe. » Altro su de.investing.com
FDA discussion on Govorestat sends Applied Therapeutics stock sharply higher
Applied Therapeutics completed a meeting with the FDA about a potential regulatory filing for Govorestat to treat CMT‑SORD. The stock jumped sharply after investors learned of the discussion; the company is now waiting for the official meeting minutes before determining next steps. Govorestat has orphan drug status from the FDA and EMA and is also being developed for other rare diseases. Applied Therapeutics has also entered an agreement for an at‑the‑market equity offering of up to USD 75 million to raise capital. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | settembre 2025 | YoY |
|---|---|---|
| Ricavi | 852,13K | - |
| Utile lordo | 852,13K | - |
| Utile netto | -16,18 Mln | - |
| EBITDA | -16,09 Mln | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 13,5 Mln € |
Numero di azioni | 144,3 Mln |
Massimo/minimo a 52 settimane | 1,36 € - 0,0818 € |
| Dividendi | No |
Beta | 2,08 |
Rapporto P/E | -0,37 |
Rapporto PEG | 0,00 |
Rapporto P/B | -26,72 |
Rapporto P/S | 14,86 |
Profilo aziendale
Applied Therapeutics, Inc., una società biofarmaceutica in fase di sviluppo clinico, sviluppa nuovi prodotti volti a trattare le malattie cardiovascolari, la galattosemia e le complicanze diabetiche. Il suo principale candidato prodotto è AT-007, che ha completato la fase 1/2 per il trattamento della galattosemia in volontari sani e adulti, ed è inoltre in studio clinico pediatrico per il trattamento della galattosemia nei bambini; per il trattamento della carenza di sorbitolo deidrogenasi; e per il trattamento dell'enzima fosfomannomutasi CDG. La società sviluppa anche AT-001, che si trova in fase III di sperimentazione clinica per il trattamento della cardiomiopatia diabetica, nonché per il trattamento della neuropatia periferica diabetica. I suoi prodotti in fase preclinica includono AT-003 per il trattamento della retinopatia diabetica; AT-104, un inibitore di PI3K per il trattamento della leucemia linfoblastica acuta a cellule T, un tumore ematologico orfano. Applied Therapeutics, Inc. è stata costituita nel 2016 e ha sede a New York, New York.
| Nome | Applied Therapeutics |
| CEO | Les D. Funtleyder |
| Sede centrale | New York City,
ny Stati Uniti |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 14/05/2019 |
| Dipendenti | 35 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | APLT |
Frankfurt | 2UV.F |
Düsseldorf | 2UV.DU |
München | 2UV.MU |